Heide Klumpp1, Jacklynn M Fitzgerald2. 1. Departments of Psychiatry and Psychology, University of Illinois at Chicago, 1747 W. Roosevelt Rd, Chicago, IL, 60608, USA. hklumpp@psych.uic.edu. 2. Department of Psychology, University of Wisconsin - Milwaukee, Milwaukee, WI, USA.
Abstract
PURPOSE OF REVIEW: Aberrant amygdala activity is implicated in the neurobiology of social anxiety disorder (SAD) and is, therefore, a treatment target. However, the extent to which amygdala predicts clinical improvement or is impacted by treatment has not been critically examined. This review highlights recent neuroimaging findings from clinical trials and research that test links between amygdala and mechanisms of action. RECENT FINDINGS: Neuropredictor studies largely comprised psychotherapy where improvement was foretold by amygdala activity and regions beyond amygdala such as frontal structures (e.g., anterior cingulate cortex, medial prefrontal cortex) and areas involved in visual processes (e.g., occipital regions, superior temporal gyrus). Pre-treatment functional connectivity between amygdala and frontal areas was also shown to predict improvement signifying circuits that support emotion processing and regulation interact with treatment. Pre-to-post studies revealed decreases in amygdala response and altered functional connectivity in amygdala pathways regardless of treatment modality. In analogue studies of fear exposure, greater reduction in anxiety was predicted by less amygdala response to a speech challenge and amygdala activity decreased following exposures. Yet, studies have also failed to detect amygdala effects reporting instead treatment-related changes in regions and functional systems that support sensory, emotion, and regulation processes. An array of regions in the corticolimbic subcircuits and extrastriate cortex appear to be viable sites of action. The amygdala and amygdala pathways predict treatment outcome and are altered following treatment. However, further study is needed to establish the role of the amygdala and other candidate regions and brain circuits as sites of action.
PURPOSE OF REVIEW: Aberrant amygdala activity is implicated in the neurobiology of social anxiety disorder (SAD) and is, therefore, a treatment target. However, the extent to which amygdala predicts clinical improvement or is impacted by treatment has not been critically examined. This review highlights recent neuroimaging findings from clinical trials and research that test links between amygdala and mechanisms of action. RECENT FINDINGS: Neuropredictor studies largely comprised psychotherapy where improvement was foretold by amygdala activity and regions beyond amygdala such as frontal structures (e.g., anterior cingulate cortex, medial prefrontal cortex) and areas involved in visual processes (e.g., occipital regions, superior temporal gyrus). Pre-treatment functional connectivity between amygdala and frontal areas was also shown to predict improvement signifying circuits that support emotion processing and regulation interact with treatment. Pre-to-post studies revealed decreases in amygdala response and altered functional connectivity in amygdala pathways regardless of treatment modality. In analogue studies of fear exposure, greater reduction in anxiety was predicted by less amygdala response to a speech challenge and amygdala activity decreased following exposures. Yet, studies have also failed to detect amygdala effects reporting instead treatment-related changes in regions and functional systems that support sensory, emotion, and regulation processes. An array of regions in the corticolimbic subcircuits and extrastriate cortex appear to be viable sites of action. The amygdala and amygdala pathways predict treatment outcome and are altered following treatment. However, further study is needed to establish the role of the amygdala and other candidate regions and brain circuits as sites of action.
Authors: J Nienke Pannekoek; Ilya M Veer; Marie-José van Tol; Steven J A van der Werff; Liliana R Demenescu; André Aleman; Dick J Veltman; Frans G Zitman; Serge A R B Rombouts; Nic J A van der Wee Journal: Eur Neuropsychopharmacol Date: 2012-06-30 Impact factor: 4.600
Authors: Katherine S Young; Lisa J Burklund; Jared B Torre; Darby Saxbe; Matthew D Lieberman; Michelle G Craske Journal: Psychiatry Res Neuroimaging Date: 2017-01-16 Impact factor: 2.376
Authors: Philippe R Goldin; Tali Manber-Ball; Kelly Werner; Richard Heimberg; James J Gross Journal: Biol Psychiatry Date: 2009-08-31 Impact factor: 13.382
Authors: David A Barton; Murray D Esler; Tye Dawood; Elisabeth A Lambert; Deepak Haikerwal; Celia Brenchley; Florentia Socratous; Jacqueline Hastings; Ling Guo; Glen Wiesner; David M Kaye; Richard Bayles; Markus P Schlaich; Gavin W Lambert Journal: Arch Gen Psychiatry Date: 2008-01
Authors: Inga Laeger; Christian Dobel; Britta Radenz; Harald Kugel; Kati Keuper; Annuschka Eden; Volker Arolt; Pienie Zwitserlood; Udo Dannlowski; Peter Zwanzger Journal: PLoS One Date: 2014-11-14 Impact factor: 3.240
Authors: Dan J Stein; Carmen C W Lim; Annelieke M Roest; Peter de Jonge; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Jordi Alonso; Corina Benjet; Evelyn J Bromet; Ronny Bruffaerts; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Josep Maria Haro; Meredith G Harris; Yanling He; Hristo Hinkov; Itsuko Horiguchi; Chiyi Hu; Aimee Karam; Elie G Karam; Sing Lee; Jean-Pierre Lepine; Fernando Navarro-Mateu; Beth-Ellen Pennell; Marina Piazza; Jose Posada-Villa; Margreet Ten Have; Yolanda Torres; Maria Carmen Viana; Bogdan Wojtyniak; Miguel Xavier; Ronald C Kessler; Kate M Scott Journal: BMC Med Date: 2017-07-31 Impact factor: 8.775
Authors: Timothy J McDermott; Namik Kirlic; Elisabeth Akeman; James Touthang; Kelly T Cosgrove; Danielle C DeVille; Ashley N Clausen; Evan J White; Rayus Kuplicki; Robin L Aupperle Journal: Neuroimage Date: 2020-06-20 Impact factor: 6.556
Authors: Julia D Buckner; Paige E Morris; Cristina N Abarno; Nina I Glover; Elizabeth M Lewis Journal: Curr Psychiatry Rep Date: 2021-04-17 Impact factor: 5.285
Authors: Hadley Rahrig; David R Vago; Matthew A Passarelli; Allison Auten; Nicholas A Lynn; Kirk Warren Brown Journal: Sci Rep Date: 2022-07-18 Impact factor: 4.996
Authors: Valerie J Sydnor; Matthew Cieslak; Romain Duprat; Joseph Deluisi; Matthew W Flounders; Hannah Long; Morgan Scully; Nicholas L Balderston; Yvette I Sheline; Dani S Bassett; Theodore D Satterthwaite; Desmond J Oathes Journal: Sci Adv Date: 2022-06-22 Impact factor: 14.957
Authors: Rany Abend; Andrea L Gold; Jennifer C Britton; Kalina J Michalska; Tomer Shechner; Jessica F Sachs; Anderson M Winkler; Ellen Leibenluft; Bruno B Averbeck; Daniel S Pine Journal: Biol Psychiatry Date: 2019-11-15 Impact factor: 13.382
Authors: Janna M Bas-Hoogendam; Henk van Steenbergen; Jennifer Urbano Blackford; Renaud L M Tissier; Nic J A van der Wee; P Michiel Westenberg Journal: Depress Anxiety Date: 2019-10-10 Impact factor: 6.505